The new issue 2/18 of our journal European Pharmaceutical Law Review (EPLR) identifies and analyses important legal and regulatory developments on the national, EU and international level. Reflecting EPLR’s position as a forum for discussion in the field of pharmaceutical law, this issue includes contributions from a number of critical stakeholders on innovation and transparency as well as reports on developments in Denmark and the Netherlands.

It also includes a case annotation on the recent Hoffman – La Roche v AGCM case and analysis of a number of cases involving EMA’s Access to Documents Policy. As always, the issue concludes with an update on legislative and policy developments in the pharma sector.

View the whole table of contents: here.